IL216147D0 - Humanized axl antibodies - Google Patents

Humanized axl antibodies

Info

Publication number
IL216147D0
IL216147D0 IL21614711A IL21614711A IL216147D0 IL 216147 D0 IL216147 D0 IL 216147D0 IL 21614711 A IL21614711 A IL 21614711A IL 21614711 A IL21614711 A IL 21614711A IL 216147 D0 IL216147 D0 IL 216147D0
Authority
IL
Israel
Prior art keywords
axl antibodies
humanized
humanized axl
antibodies
Prior art date
Application number
IL21614711A
Other versions
IL216147A (en
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP09006355A priority Critical patent/EP2270053A1/en
Priority to EP09006474 priority
Priority to PCT/EP2010/056487 priority patent/WO2010130751A1/en
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of IL216147D0 publication Critical patent/IL216147D0/en
Publication of IL216147A publication Critical patent/IL216147A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL216147A 2009-05-11 2011-11-03 Humanized axl antibodies IL216147A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Publications (2)

Publication Number Publication Date
IL216147D0 true IL216147D0 (en) 2012-01-31
IL216147A IL216147A (en) 2016-04-21

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216147A IL216147A (en) 2009-05-11 2011-11-03 Humanized axl antibodies

Country Status (15)

Country Link
US (2) US8841424B2 (en)
EP (1) EP2430050A1 (en)
JP (2) JP5909442B2 (en)
KR (1) KR20120035145A (en)
CN (1) CN102421802B (en)
AR (1) AR076564A1 (en)
AU (1) AU2010247464B2 (en)
BR (1) BRPI1013428A2 (en)
CA (1) CA2759836A1 (en)
IL (1) IL216147A (en)
MX (1) MX2011011825A (en)
RU (2) RU2571224C2 (en)
TW (2) TWI526223B (en)
WO (1) WO2010130751A1 (en)
ZA (1) ZA201107529B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571224C2 (en) * 2009-05-11 2015-12-20 УЗ ФАРМА ГмбХ Humanised anti-axl antibodies
EP2483289B1 (en) 2009-10-02 2019-03-20 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
JP6120833B2 (en) * 2011-06-22 2017-04-26 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) Anti-Axl antibodies and their use
EP2723376B1 (en) * 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
AR093357A1 (en) * 2012-11-05 2015-06-03 Pf Medicament Antigen binding proteins and their use as addressing product for treating cancer
US9822347B2 (en) * 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US20180326084A1 (en) 2015-07-10 2018-11-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US20180134793A1 (en) * 2015-05-18 2018-05-17 Agensys, Inc. Antibodies that bind to axl proteins
RU2678569C1 (en) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Method of pressing the tumors metastasis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (en) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostic proof using chimair antibodies
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
DE69734109T2 (en) * 1996-03-20 2006-06-29 Immunomedics, Inc. Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and its use as a cancer vaccine and for labeling
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc Antibodies directed to c-MET
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
DE602005026219D1 (en) 2004-10-01 2011-03-17 Max Planck Gesellschaft Against the mammal-Eag1 ion channel protein antibodies directed
NZ561137A (en) 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
RU2415151C2 (en) * 2005-06-07 2011-03-27 Эсбатек Аг STABLE AND SOLUBLE ANTIBODIES, INHIBITING TNFα
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
JP2011514881A (en) * 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ Using tam activator as used and immunosuppressive agents tam receptor inhibitor as an immune enhancer
US8933202B2 (en) * 2007-11-12 2015-01-13 U3 Pharma Gmbh AXL antibodies
RU2571224C2 (en) * 2009-05-11 2015-12-20 УЗ ФАРМА ГмбХ Humanised anti-axl antibodies

Also Published As

Publication number Publication date
AU2010247464A1 (en) 2011-11-10
EP2430050A1 (en) 2012-03-21
US20120117670A1 (en) 2012-05-10
JP2016011306A (en) 2016-01-21
KR20120035145A (en) 2012-04-13
MX2011011825A (en) 2011-12-06
AU2010247464B2 (en) 2014-09-11
ZA201107529B (en) 2012-06-27
RU2571224C2 (en) 2015-12-20
TW201105348A (en) 2011-02-16
US20150037323A1 (en) 2015-02-05
IL216147A (en) 2016-04-21
JP5909442B2 (en) 2016-04-26
US8841424B2 (en) 2014-09-23
RU2015147287A (en) 2017-05-12
AR076564A1 (en) 2011-06-22
TWI526223B (en) 2016-03-21
BRPI1013428A2 (en) 2019-07-02
CA2759836A1 (en) 2010-11-18
JP2012526530A (en) 2012-11-01
WO2010130751A1 (en) 2010-11-18
TW201509431A (en) 2015-03-16
CN102421802B (en) 2014-08-20
RU2011150183A (en) 2013-06-20
CN102421802A (en) 2012-04-18

Similar Documents

Publication Publication Date Title
TWI461314B (en) Vehicle
TWI564304B (en) Anti-cd38 antibodies
TWI402078B (en) Antibodies against csf-1r
TWI461211B (en) Anti-her antibodies
IL214885D0 (en) Bispecific anti-erbb-1/anti-c-met antibodies
IL215062D0 (en) Bispecific anti-erbb-3/anti-c-met antibodies
ZA201106503B (en) Antibody formulation
IL214884D0 (en) Trivalent, bispecific antibodies
SI2411408T1 (en) Soluble "heavy-chain only" antibodies
JP2009106306A5 (en) Anti-PDGFRα antibody
IL222272A (en) Anti-erbb3 antibodies
GB201103955D0 (en) Antibodies
PL2581113T3 (en) Anti-tim-3 antibody
HK1182625A1 (en) Bispecific antibodies
ZA201102119B (en) Improved antibody libraies
IL221408D0 (en) Monoclonal antibodies against c-met
HK1187928A1 (en) Antibodies recognising phospho-tau -tau
EP2473531A4 (en) Anti-gitr antibodies
TWI471139B (en) Anti-igf antibodies
EP2409990A4 (en) Antibody constant region variant
HK1168791A1 (en) Substituted imidazoquinoxalines
IL205607D0 (en) Axl antibodies
PT2406284T (en) Anti-bcma antibodies
EP2431393A4 (en) Anti-axl antibody
TWI423818B (en) Cgrp antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed